Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 14/20 | 0.69 |
| ▸ | F7 | P08709 | 18/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 12/20 | 0.56 |
| ▸ | PRSS2 | P07478 | 12/20 | 0.56 |
| ▸ | PRSS3 | P35030 | 12/20 | 0.56 |
| ▸ | F3 | P13726 | 11/20 | 0.56 |
| ▸ | F2 | P00734 | 10/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7148989 | 0.93 | F10 (0.60) | F10F7PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL7148983 | 0.93 | F10 (0.60) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL7153043 | 0.88 | F10 (0.66) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL6873047 | 0.88 | F10 (0.66) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL7143434 | 0.87 | F10 (0.73) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL7147264 | 0.87 | F10 (0.73) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL5882814 | 0.87 | F10 (0.73) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL6873058 | 0.86 | F10 (0.66) | F10F7PRSS1PRSS2PRSS3 | |
| Hydrochloric Acid SCHEMBL5882762 | 0.86 | F10 (0.72) | F10F7PRSS1PRSS2PRSS3 | |
| SCHEMBL7150328 | 0.83 | F10 (0.81) | F10F7PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6642386-B2 | Having alkoxy, halo and piperidin-4-yl substituents; water soluble; coagulation factors Xa and IXa, thrombin induced factor VIIa and tissue factor inhibitors | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | claimed |
| US-20030166683-A1 | N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | claimed |
| US-6642386-B2 | Having alkoxy, halo and piperidin-4-yl substituents; water soluble; coagulation factors Xa and IXa, thrombin induced factor VIIa and tissue factor inhibitors | HOFFMANN-LA ROCHE INC. | 2003-11-04 | — | — | US | disclosed |
| US-20030166683-A1 | N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166683-A1 | N-(4-CARBAMIMIDOYL-PHENYL)-GLYCINE DERIVATIVES | F2, F12, F5 | F10 7/4885F7 5/4885PRSS1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.